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Introduction 
Temazepam is one of the most-used hypnotics world 
wide. Only oral formulations of temazepam are com- 
mercially available: a powder-filled capsule and a liq- 
uid-filled capsule, the latter showing a more rapid 
absorption than the former [l 21. 
In clinical practice, the liquid-filled temazepam cap- 
sules are occasionally administered rectally in patients 
for hypnotic purposes, when oral intake is not pos- 
sible. No data, however, are available on the rectal 
use of these capsules. 
Several authors have descibed rectal administration 
of benzodia zepines such as diazepam, flunitrazepam 
and nitrazepam (for a review see [3]). Fucella [4] pub- 
lished in 1972 a study in four volunteers on the bio- 
availability of temazepam after rectal administration 
in a suppository, in comparison with the oral use of 
temazepam in a capsule and a solution. The bioavail- 
ability of temazepam from suppositories ranged 
between 57%-90% of the bioavailability of temaze- 
pam from the capsules. However, the composition of 
neither the suppository base, the capsule nor the oral 
solution was mentioned. 
The aim of this study was to develop a suitable rec- 
tal formulation for temazepam by determination of 
pharmacokinetic data in volunteers after rectal 
administration of three formulations of temazepam: a 
suppository, a micro-enema and a commercially avail- 
able liquid-filled capsule. Oral use of the liquid-filled 
capsule was used as a reference. An in vitro study with 
temazepam in three different suppository bases was 
undertaken and release parameters were determined 
in order to select a suitable suppository base for in 
vivo testing. The release profile of the liquid-filled cap- 
sule was determined in vitro to allow comparison of in 
vivo-in vitro data. 
Methods 
In vitro study 
In vitro release of temazepam from three different 
suppositories and the liquid-filled capsule 
(Normison@, Wyeth Laboratoria, Hoofddorp, the 
Netherlands) was studied using the paddle apparatus, 
modified by Cox [3]. Demineralised water (1000 ml) 
was used as dissolution medium at a temperature of 
37 f 0.5 “C. Stirring rate was adjusted to 60 rpm. 
Temazepam suppositories (2.3 ml) were extempo- 
rarily prepared with the following bases: polyethylene 
glycol (PEG) 1540, PEG 1540:4000 (2:l) and fatty 
base (Witepsol H15). All compounds were obtained 
from Bufa Chemicals, Uitgeest, the Netherlands. The 
liquid-filled capsules contained a solution of temaze- 
pam in polyethylene glycol and glycerol in a soft gela- 
tin capsule. All formulations contained 10 mg of 
temazepam and complied with the 95-l 05% content 
range and the test on uniformity of content on single- 
dose preparations, described in Eur.Ph. 2nd ed. [5]. 
Each suppository or liquid-filled capsule was 
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An in vitro/in vivo study was carried out with different rectal 
formulations of temazepam. Pharmacokinetic data were 
determined in a cross-over study in 10 volunteers after rectal 
administration of 10 mg temaz;pam as a polyethylene glycol 
based suppository (selected from in vitro data), a liquid-filled 
capsule d&l a mi&o-enema respectively, using oral 
administration of a liquid-filled capsule as a reference. 
Serum levels of temazepam indicate an instantaneous and 
complete release from the micro-enema (F&).94 f0.21, 
C may 205 *36.9 WI, tmax 0.49 kO.31 hour) and a slower but 
comolete release of temazeaam from the suooositorv 
(F,,:l .Ol kO.25, C,,, 202 $41.3 pg,‘l, &, i :48 20.21 
hour). A high intenndividual variation in absorption profiles 
was observed after rectal administration of the liquid-filled 
capsule (F,,, 0.72 f0.36, C,,, 182 fl22 fig/l, t,,, 4.08 
k4.28 hour), which makes it less suitable for rectal use. 
The micro-enema and suppository appear to be useful as 
rectal formulations for temazepam. 
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immersed 2 cm below the dissolution medium at t = 
0. Samples of the dissolution medium were taken at 
t = 0; 2.5; 5; 7.5; 10; 15; 20; 25; 30 min. 
Samples were analysed by measuring absorbance 
at 230 nm (Hitachi spectrophotometer 150-20 in 
combination with Hitachi Data processor 150-20, 
Merck, Nieuwekerk a/d IJssel, the Netherlands). 
Standards of temazepam (12.5, 6.25, 3.125 and 
1.562 mg/l temazepam in water) were prepared by 
dilution of a stock solution of temazepam 250 mg/l in 
methanol:water (150:350). Lower assay limit was 0.5 
mg/l, correlation coefficient of the calibration curves 
was 0.9998 (N=6). 
For each formulation, release profiles were deter- 
mined (N=7 for the suppositories, n=8 for the liquid- 
filled capsule). Release parameters were calculated 
with the software program WEIFIT [6], according to 
the formula F = Fu.(l -e-[(t-To/Td]R), in which 
F = amount released at time t (mg) 
Fu = amount released after infinite time (mg) 
TO = lag time (min) 
Td = time to release 63.2% of the total dose (min) 
R = shape parameter 
t = time (min) 
Statistical analysis 
Differences in means of Fu, TO and Td of the formula- 
tions were analysed for statistical significance by 
Student’s t-test for unpaired data. P values < 0.05 
were considered as statistically significant. 
In vivo study 
Study population 
The study was conducted at the hospital ‘Medisch 
Spectrum Twente’ in Enschede, the Netherlands. 
Ten healthy, male volunteers between 21 and 52 
years participated in the study on a informed consent 
base. Excluded were subjects with known intolerance 
to benzodiazepines. 
The study was approved by the local Institutional 
Review Board. 
Study design 
A cross-over design was used in the study in order to 
minimize interindividual differences. 
The suppository, micro-enema and liquid-filled 
capsule were self-administered rectally by each volun- 
teer in randomized order. Oral administration of the 
liquid-filled capsule took place after overnight fasting, 
after which volunteers continued fasting for another 3 
hours. 
A wash-out period of one week was maintained 
between the administration of the different formula- 
tions. During the first hour after rectal administration 
the volunteers stayed in lying position, in order to 
minimize variability in rectal absorption. 
After completion of the study, volunteers were 
asked for their preference in rectal formulations, with 
regard to handling and comfort. 
Dosage forms 
Based on the data of the in vitro study (see Results), 
temazepam suppositories (2.3 ml) were prepared in a 
polyethylene glycol 1540 base. 
The micro-enema contained temazepam in a 2 ml 
solution of glycofurol:ethanol 96%:water (5:1:4), sim- 
ilar to the composition of diazepam micro-enemas 
[3]. Methylhydroxybenzoate (0.15%) was added as a 
preservant. The liquid-filled capsule (Normison@) was 
used both orally and rectally. 
All preparations contained 10 mg of temazepam. 
Sample collection 
A catheter (Insyte-W 1.3 x 32 mm, Vialon@, Becton 
Dickinson, USA) was inserted in a forearm vein to 
facilitate venous blood sampling. Samples were 
obtained prior to temazepam administration and at 
0.08a, 0.16”, 0.25, 0.5, 1.0, lSb, 2.0, 3.0b, 4.0, 6.0, 
8.0, 10.0, 24.0 hours after temazepam administration 
(amicro-enema, bliquid-filled capsule rectally). Each 
time, 5 ml blood were collected in a glass tube 
(Venoject@, Terumo, Leuven, Belgium) and centri- 
fuged, after clotting. The serum samples were stored 
at -20 “C in polypropylene tubes (Sarstedt, 
Numbrecht, Germany) until analysis. 
Assay 
Serum levels of temazepam and oxazepam, a very 
minor metabolite, were determined using a reversed- 
phase high performance liquid chromatography 
system (Perkin-Elmer Series 10 Liquid Chroma- 
tography), provided with an autosampler (Perkin- 
Elmer ISS-101, Amsterdam, the Netherlands) [7, 
modified]. 
One ml of serum was mixed with 100 ~1 internal 
standard (camazepam 2 mg/l in methanol:water 
[150:350]) and 0.4 ml sodium borate buffer pH 9.0 
(Na,B,O,*lOHzO O.OSM:HCI O.lN [85:15]). 5 ml of 
dichloromethane were added as extraction medium. 
The mixture was shaken for 15 min, and centrifuged 
for 5 min at 1800s. The organic phase was evaporat- 
ed under a flow of nitrogen. After reconstitution in 
100 ~1 of mobile phase (methanol:acetonitriI: potas- 
siumdihydrogenphosphate 0.05M [440:165:570]), 
60 ,ul were injected on a LiChrosphere lOORP-18 (5 
pm) column (Merck 50943). At a flow rate of 1.5 
ml/min, retention times of oxazepam, temazepam 
and camazepam were respectively 4.3, 5.5 and 11.5 
min. The absorbance was monitored at wavelength 
230 nm, using a Perkin-Elmer LC-75 spectrophotom- 
eter (Amsterdam, the Netherlands). All chemicals 
were obtained from Merck, Darmstadt, Germany. 
Two sets of standards (serum, spiked with 10, 25, 
50,100,200,400 pg/l of oxazepam and temazepam) 
and two control sera (KKCT: Association for External 
Quality Assessment in TDM & Toxicology, the Hague, 
the Netherlands) were run with each batch of sam- 
ples. Using the standard curves, serum concentrations 
were calculated with Turbochrom III (Perkin-Elmer) 
software system. The assay was validated for the 
serum level-range between 10 pg/l and 400 pg/l for 
oxazepam and temazepam [8]. 
Recovery of oxazepam and temazepam was 92.4% 
and 96.7% respectively. The lower assay limit was 10 
pg/l, the limit of detection was 2 pg/l for both oxa- 
zepam and temazepam. The standard deviation (y) of 
the assay, in relation to the serum level (x), was 
described by the following polynome y  = 2.01 + 
5.27*10m3x + 7.27*1O-5x2 -6.38*10w8x3 (n=6) for 
temazepam and y= -0.09 + 9.99’1 Om2x - 5.71 *l Os4x2 
+ 1.07*1 Oe6x3 (n=6) for oxazepam. 
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Figure 1 
In vitro release profiles of rectal formulations of 7 0 mg Temazepam. 
Pharmacokinetic and statistical analysis 
Pharmacokinetic parameters were calculated with the 
software program KINFIT (Mediwarea, Groningen, 
the Netherlands). Non-linear curve fitting based on a 
two-compartment model provided an estimation of 
peak concentration (Cmax bg/l]), time to peak con- 
centration t,,, [hour], lag time [hour], absorption 
rate constant ka [l/hour], clearance Cl [l/hour], elimi- 
nation half-life tl/z el. [hour] and area under the curve 
(AUC [hour.pg/l], t=O-24 hour) calculated by the 
trapezoidal rule. The relative bioavailability (F,,) was 
calculated by dividing the AUC of the rectal formula- 
tion by the AUC after oral intake of the liquid-filled 
capsule. The cumulative input of the different rectal 
formulations was calculated by numerical deconvolu- 
tion, using the software program KINBES. The mean 
differences of the interindividual parameters using 
rectal formulations were tested for statistical signifi- 
cant differences with the results after oral administra- 
tion, using the Student’s t-test for paired data (P < 
0.05). 
Results 
In vitro study 
The release profiles are shown in Figure 1. Release 
parameters, calculated by WEIFIT, are summarized in 
Table 1. Despite complete melting of the supposito- 
ries within 10 minutes, release of temazepam from 
the fatty base was incomplete and inconsistent and 
release parameters could not be calculated by curve- 
fitting. The suppositories with polyethylene glycol 
bases showed a reproducible and complete release of 
temazepam within 30 minutes. No significant differ- 
ences in Fu were found between the two polyethy- 
lene glycol bases. However, Td of the polyethylene 
glycol 1540 base was significantly lower than Td of 
the polyethylene glycol 1540:4000 base, indicating a 
faster release of temazepam from polyethylene glycol 
1540. The liquid-filled capsules showed an inconsis- 
tent release with a high variation in lag-time and Td 
between the capsules tested. However, within 20 
minutes the release process was completed. 
In vivo study 
All volunteers completed the study. No side-effects 
were experienced, except for a slight drowsiness in 
some volunteers. 
The serum concentration-time profiles and the 
cumulative input of the different rectal formulations 
and the oral formulation are shown in Figure Za-d. 
The mean pharmacokinetic parameters and their cor- 
responding standard deviations are summarized in 
Table 2. 
The AUC of both micro-enema and suppository did 
not differ significantly from the AUC of the oral cap- 
sule, indicating an equivalent bioavailability. 
However, the AUC after rectal administration of the 
capsule, was significant lower (P~0.05) than the AUC 
after oral administration. After administration of the 
micro-enema absorption started almost immediately. 
In comparison to the micro-enema and the oral 
capule, the suppository showed a slower absorption 
process (ka 1.5 f  1.3 hour-‘) and a significant higher 
t,,, (1.5 f  0.4 hour). 
The liquid-filled capsule showed an highly erratic 
absorption-profile after rectal administration. Only 
minor absorption occurred in five of the ten volun- 
teers, with hardly any absorption in two volunteers. 
The other volunteers showed absorption-profiles 
comparable with oral intake. Serum-concentrations of 
oxazepam were below quantification levels in all sam- 
ples. The observed pharmacokinetic parameters after 
oral administration of the liquid-filled capsule: Cl 81 f  
25 ml/kg/hour and tl/z el. 9.3 -I- 5.4 hour (Table 2, Cl 
corrected for body-weight of the volunteers) were 
similar to data reported in literature (Cl 60-120 
ml/kg/hour, t1/2 el. 6-11 hour) [9]. 
Table 1 In vitro release parameters (i standard deviation) of 10 mg temazepam in different rectal 
formu/ations. 
liquid-filled capsule PEG 1540 PEG 7 540:4000 
FU 12.1 +1.92 9.6 +0.40’ 10.7 k1.90’ 
Td 13.1 f7.82 8.6 +0.54# 14.4 zk5.12” 
R 2.2 f0.55 1.5 kO.08 1 .l f0.12 
TO 0.3 f0.62 0.0 fO.OO 0.4 kO.68 
* Fu (PEG1 540) not statistically significant different from Fu (PEG 1540/4000). 
+! Td (PEG1 540) significantly shorter than Td (PEG1 540/4000) (PC 0.01). 
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Serum-concentration vs. time profiles and cumulative input 
(expressed in relative units, compared to oral input) after rectal 
administration of 7 0 mg temazepam in a liquid-filled capsule 
(n=7 0). 
Figure 2a 
Serum-concentration vs. time profiles after oral administration of 
7 0 mg temazepam in a liquid filled capsule (n= 7 0). 
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Serum-concentration vs. time profiles and cumulative input Serum-concentration vs. time profiles and cumulative input 
(expressed in relative units, compared to oral input) after rectal (expressed in relative units, compared to oral input) after rectal 
administration of 7 0 mg temazepam in a PEG suppository administration of 10 mg temazepam in a 
(n=70). glycofural/ethanol/water enema (n= 7 0). 
Table 2 Mean pharmacoMnet~c parameters (k standard deviation) after oral and rectal administration of 
70 mg temazepam in different brmulations to 10 volunteers 
Pharmacokinetic Capsule Capsule 




tzx F [hour] 
%7,, hA 
lag-time [hour] 
ka [I /hour] 
V/z el. [hour] 
Cl [l/hour] 
1540*413 1170-1735 1400 f  272 1510-1: 334 
0.8 1 .o* f  0.6 4.1 0.72 *4.3+ f  0.36# 0.94 5 f  f  0.3” 0.21* 1 .5 Ol f  + 0.4# 0.25* 
326 f  76.6 182rt 122+ 205 f  36.9+ 202 + 41.3+ 
0.2 f  0.2 2.7 f  4.2’ 0.01 + 0.02+ 0.1 +0.1* 
37.3 f  67.5 6.9 f  9.8 15.6 + 25.9 1.5 f  1.3 
9.3 f  5.4 ll.Of4.1* 7.6 f  5.7’ 14.1 f  6.7’ 
6.4 f  2.0 8.5 f  4.6* 7.5 f  2.3* 5.9 * 2.0* 
* By definition 1 .O. 
l Not statistically significant from capsule orally. 
* p c 0.05 compared to capsule orally. 
+ p < 0.01 compared to capsule orally. 
Cl and tl/z el. of the rectal formulations did not dif- 
fer significantly from Cl and tl/z el. after oral adminis- 
tration, justifying the use of oral data as reference- 
data. 
With respect to handling of the drugs, the self- 
administration of the capsule was experienced as 
most difficult (r-1=9) because of ‘sliding problems’ and 
the suppository as most easy (r-1=9). With regard to 
comfort, 5 volunteers reported no discomfort with 
any of the rectal formulations. Minor local irritation 
was experienced with the suppositories (r-1=3), the 
enema (n=l) and the capsule (n=l). 
Discussion 
In vitro study 
The release data from the polyethylene glycol bases 
correspond with the expected optimal release of 
hydrophobic compounds like temazepam from a 
water-soluble base like PEG [3]. Comparing the PEG 
bases studied, the fastest release of temazepam is 
obtained with the PEG 1540 base, as quantified by 
the lowest Td. These findings correlate with a higher 
melting point of a suppository base composed of a 
mixture of PEG 1540 and PEG 4000 compared to 
purely PEG 1540. Release of temazepam from a fatty 
base was slow, probably due to adherence of the 
hydrophobic compound to the base and wetting 
problems. Similar results have been found for the rele- 
ase of diazepam from a fatty base [IO]. An almost 
instantenous release of temazepam from the liquid- 
filled capsules was shown due to ‘bursting’ of the cap- 
sule, but the period to release varied from 5 to 15 
minutes after immersing the capsule. An explanation 
for these differences is difficult to give, however slight 
sticking of the capsule to the immersing device may 
have influenced the release process. Therefore, the 
results of the capsule were not included in the statisti- 
cal analysis. 
In vivo study 
For patients who cannot take a hypnotic orally, a rec- 
tal formulation can be an easy and safe alternative to 
parenteral administration of a benzodiazepine. In the 
literature [3], rectal administration of benzodiaze- 
pines for purposes other than hypnotic use, has 
shown to be effective: a diazepam enema and a mi- 
dazolam enema were effective as anti-epileptic and 
pre-medication respectively. 
A optimal rectal formulation of a drug for hypnotic 
purposes should have the following characteristics: 
non-irritant, easy to prepare and to (self)-administer, 
no lag-time, a short t,,, and an bioavailability equiva- 
lent to oral use. 
The hypnotic temazepam has the advantages of an 
intermediate tl/z el. (6-l 1 hour), no active meta- 
bolites (in clinically relevant concentrations) and a 
worldwide experience of many years. Considering the 
need for a rectal hypnotic, development of a suitable 
rectal formulation of temazepam could mean a signif- 
icant improvement in clinical practice. 
In this study, none of the patients fell asleep after 
using either rectal or oral formulation of 10 mg 
temazepam. These findings are consistent with other 
day-time studies with hypnotics. Since no objective 
hypnotic effects were studied, no conclusions can be 
drawn on hypnotic effects of either formulation, other 
than interpretating the pharmacokinetic data. 
Looking only at the C,,, of temazepam, obtained 
with the rectal formulations, none of the formulations 
appears to be in the therapeutic range described in 
literature (300-800 pug/l) [I I]. However, a clear rela- 
tion between serum levels and hypnotic effect has 
never been established for temazepam. An effective 
rectal dosage of temazepam should probably be 
higher than 10 mg (f.i. 20 mg), but this has to be 
confirmed in pharmacodynamic studies. Considering 
the results found in this study, the micro-enema 
appears to be the optimal rectal formulation for 
temazepam with a short t,,, and a F,,, equivalent to 
I. Taking into account the ease of self-administration 
and the ease of pharmaceutical (bulk-)preparation, 
the PEG-suppository appears to be a possible alterna- 
tive formulation, if accepting its longer t,,, and thus 
a slower therapeutic effect. 
Temazepam from rectally administered liquid-filled 
capsules was overall unpredictably and inconsistently 
absorbed, despite good results in some individuals. 
Since oral absorption was fast and reproducible, it is 
therefore likely that the small volume of fluid in the 
rectum may be the limiting step in the absorption 
process of rectally administered capsules. Also, the 
intraluminal pressure may have a small influence on 
the release profiles of rectally administered drugs. 
Apparently, these factors were highly variabel within 
the tested population, resulting in an variable lag- 
time and bioavailability of temazepam in rectally 
administered liquid-filled capsules. Apart from the 
pharmacokinetic aspects, the difficulties in (self-) 
administration makes the liquid-filled capsule unsuit- 
able for rectal use. The current practice of rectal 
administration of temazepam in a liquid-filled capsule 
should therefore be discouraged. 
Conclusion 
Based on pharmacokinetic data, rectal administration 
of temazepam can be effective, dependent on the for- 
mulation used. 
Both the micro-enema, containing temazepam in a 
solution of ethanol, glycofurol and water, and the 
suppository with a polyethylene glycol base, can be 
used as rectal formulations of temazepam. Further 
pharmacodymanic studies are needed for determina- 
tion of the proper dosage. The commercially avail- 
able, liquid-filled capsule is less suitable for rectal 
administration. 
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“AIDS Clinical Trials” is intended for use by clinicians 
and statisticians in order to gain more insight into the 
design, conduct and interpretation of clinical trials in 
populations infected with HIV. The book does not 
attempt to provide a background for the basic prin- 
ciples of clinical trials; specific aspects involving clini- 
cal trials in the HIV-infected population are highligh- 
ted. AIDS is different from other life-threatening dise- 
ases for which treatments are routinely studied in cli- 
nical trials. Infection with HIV is a chronic illness, 
making a long follow-up period necessary to detect 
improvement of for instance survival. However, cur- 
rent clinical practice is changing rapidly according as 
our knowledge of the pathogenesis of the virus is 
increasing. New antiretroviral drugs, drugs to treat 
opportunistic infections or HIV-related malignancies 
become available to scientists. These scientists are 
confronted with a generally well informed population 
that demands right of say in the design of clinical 
trials and puts pressure upon the access of new drugs. 
These issues generate intense and often conflicting 
concerns for scientists designing clinical trials to eva- 
luate AIDS therapies. 
The book has been divided in five parts. The first 
part gives an overview of the history and course of 
HIV-infection and the design of traditional trials and 
trials regarding the accelerated approval program of 
the FDA. 
In the second and most voluminous part, the 
design of the study protocol, aspects regarding quali- 
ty of life, selection of endpoints, and the use of CD,+ 
lymphocyte count as a measure of efficacy are discus- 
sed. Furthermore, statistical issues like sample size cal- 
culations, interim monitoring and the analysis of data 
from trials with combinations of drugs are reviewed. 
An excellent chapter regarding the statistical backg- 
round of equivalence trials (a design often used in this 
area) is provided. The third part gives insight into spe- 
cific problems encountered in trials in HIV-infected 
women and children. In the fourth part prophylactic 
HIV vaccine trials and large simple trials of HIV thera- 
pies are considered. The book is completed with a 
description of trials with an economic or epidemiolo- 
gical objective. 
Altogether, a broad ovetview is presented of the 
design, conduct and analysis of clinical trials in HIV 
infected individuals. Both clinicians and statisticians 
will find interesting knowledge of statistics and medi- 
cal practice, respectively; however, they will not find 
much new information regarding their own profes- 
sion. 
In general, literature references are up to date. 
Some aspects are described repeatedly in several 
chapters. Furthermore, regarding the registration of 
antiretroviral drugs, the book is aimed at the United 
States of America. Any reference to registration aut- 
horities other than the FDA is lacking. 
“AIDS Clinical Trials” can be recommended to clini- 
cians interested in statistics and statisticians who need 
clinical background information. Besides, the book 
will provide useful information to anyone interested 
in clinical trials in the HIV infected population. 
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